SNC-80

SNC-80, frequently stylized with a hyphen, is a synthetic cannabinoid drug that acts as a potent agonist of the CB2 receptor, and a weaker agonist of the CB1 receptor. It is a structural analog of JWH-018, differing primarily by the replacement of the naphthoyl group with an adamantoyl group. This structural modification significantly shifts the receptor selectivity, favoring CB2 over CB1.

The drug's primary use has been in scientific research investigating the role of the CB2 receptor in various physiological processes. It has been used in animal models to study pain, inflammation, and immune system modulation. The adamantane moiety present in the molecule contributes to improved metabolic stability compared to other synthetic cannabinoids.

While SNC-80 exhibits lower psychoactivity than CB1-selective cannabinoids due to its preferential binding to CB2 receptors, it is still a controlled substance in many jurisdictions. Its potential for abuse remains a concern, although less pronounced than for substances with strong CB1 activity. The long-term effects of SNC-80 use are not fully understood, and research is ongoing to elucidate its pharmacological profile and potential therapeutic applications.